Piflufolastat approved as diagnostic tool for adults with prostate cancer

Twitter

Linkedin

Facebook

email

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.

Follow this news feed: